IRIDEX Corporation
IRIX Healthcare Medical Devices
IRIDEX Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, up 8.23% from fiscal 2024. In the quarter to June 2026, revenue fell 7.41%, EPS fell 16.7%, free cash flow grew 130.2% and total debt rose 3.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IRIX
IRIDEX Corporation (IRIX) Piotroski F-score
IRIDEX Corporation's Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, up from 2 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 2.00 |
| FY2024 | 2 | (1.00) |
| FY2023 | 3 | 1.00 |
| FY2022 | 2 | (3.00) |
| FY2021 | 5 | 0.00 |
| FY2020 | 5 | 1.00 |
| FY2019 | 4 | 0.00 |
| FY2018 | 4 | 2.00 |
| FY2017 | 2 | (2.00) |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (15.22%) | (28.03%) | Fail | 0 |
| Positive operating cash flow | (2.11m) | (7.28m) | Fail | 0 |
| Rising return on assets | (15.22%) | (28.03%) | Pass | 1 |
| Cash flow above net income | 2.32m | 1.63m | Pass | 1 |
| Falling long-term leverage | 0.13 | 0.03 | Fail | 0 |
| Rising current ratio | 1.91 | 1.42 | Pass | 1 |
| No new shares issued | 16,934,000 | 16,439,000 | Fail | 0 |
| Rising gross margin | 36.50% | 40.07% | Fail | 0 |
| Rising asset turnover | 1.81 | 1.53 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| BTCY Biotricity Inc. compare | 5 |
| HSCS HeartSciences Inc. compare | 4 |
| IRIX IRIDEX Corporation | 4 |
| LFWD Lifeward Ltd. compare | 4 |
| PETV PetVivo Holdings, Inc. compare | 3 |
| ALUR Allurion Technologies, Inc. compare | 2 |
| SINT SINTX TECHNOLOGIES, INC. compare | 2 |
| RBOT Vicarious Surgical Inc. compare | — |
| BDMD Baird Medical Investment Holdings Limited compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover